1. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation
- Author
-
Wang, Jing, Peng, Yan, Sun, Hongxia, Aung, Phyu P., Resetkova, Erika, Yam, Clinton, Sahin, Aysegul A., Huo, Lei, and Ding, Qingqing
- Subjects
Immunohistochemistry -- Analysis ,Progesterone -- Analysis ,Carcinoma -- Analysis ,Cancer -- Analysis ,Estrogen -- Analysis ,Breast cancer -- Analysis ,Epidermal growth factor -- Analysis ,Health - Abstract
* Context.--The recently identified immunohistochemical marker TRPS1 is highly sensitive and specific for invasive breast carcinoma, especially triple-negative breast carcinoma. However, TRPS1 expression in special morphologic subtypes of breast cancer is unclear. Objective.--To investigate the expression of TRPS1 in invasive breast cancer with apocrine differentiation, in comparison to the expression of GATA3. Design.--A total of 52 invasive breast carcinomas with apocrine differentiation, comprising 41 triple-negative breast carcinomas and 11 estrogen receptor (ER) and progesterone receptor (PR)-negative, human epidermal growth factor receptor 2 (HER2)-positive cases, along with 11 triple-negative breast carcinomas without apocrine differentiation, were evaluated for TRPS1 and GATA3 expression by immunohistochemistry. All tumors were diffusely positive (>90%) for androgen receptor (AR). Results.--Triple-negative breast carcinoma with apocrine differentiation had positive TRPS1 expression in 12% of cases (5 of 41), whereas GATA3 was positive in all cases. Similarly, [HER2.sup.+]/[ER.sup.-] invasive breast carcinoma with apocrine differentiation showed positive TRPS1 in 18% of cases (2 of 11), whereas GATA3 was positive in all cases. In contrast, triple-negative breast carcinoma with strong AR expression but without apocrine differentiation showed both TRPS1 and GATA3 expression in 100% (11 of 11) of cases. Conclusions.--Most [ER.sup.-]/[PR.sup.-]/[AR.sup.+] invasive breast carcinomas with apocrine differentiation are TRPS1 negative and GATA3 positive, regardless of HER2 status. Therefore, TRPS1 negativity does not exclude breast origin in tumors with apocrine differentiation. A panel of TRPS1 and GATA3 immunostains can be helpful when the tissue origin of such tumors is clinically relevant. (Arch Pathol Lab Med. 2024;148:200-205; doi: 10.5858/arpa.2022-0289-OA), The recently identified breast marker TRPS1 is more sensitive and specific than the widely used breast cancer markers, including GATA3. (1) TRPS1 (trichorhinophalangeal syndrome 1, also known as transcriptional repressor [...]
- Published
- 2024
- Full Text
- View/download PDF